Corcept's miricorilant MASLD Phase 1 study completed, University of Missouri site
A Phase 1 trial testing miricorilant's effect on liver fat in presumed MASH patients has reached completed status, with results posted.
Corcept Therapeutics had one notable registry update this week involving its investigational drug miricorilant.
- Corcept's Phase 1, open-label study (NCT06947304) evaluating miricorilant's effect on hepatic lipids in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 is listed as completed. The trial enrolled 9 participants who received 100 mg of miricorilant every day for 6 weeks1, with change in liver fat content by MRI-PDFF after 6 weeks of treatment1 tracked as a secondary outcome. The study is sponsored by Corcept Therapeutics, with University of Missouri-Columbia as a collaborator1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.